Seagen to highlight overall survival data for padcev® and tivdak® during presidential symposium at esmo congress 2023

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced the upcoming presentation of detailed results from two pivotal phase 3 studies at the esmo congress 2023. results from the ev-302 study of padcev (enfortumab vedotin-ejfv) plus keytruda® (pembrolizumab) in locally advanced or metastatic urothelial cancer (la/muc) in the first-line setting will be presented during a presidential symposium at the congress. seagen will also present results from the innovatv 301 study of ti.
SGEN Ratings Summary
SGEN Quant Ranking